CTOs on the Move


 
The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.vocare.com
  • 8888, Keystone Crossing
    Indianapolis, IN USA 46240
  • Phone: 317.658.0005

Executives

Name Title Contact Details

Similar Companies

MIND 24-7

MIND 24-7 is fundamentally changing the landscape of accessible behavioral health by offering walk-in urgent mental health and substance abuse services such as Psych Express Care, Psych Crisis Care, and Psych Progressions. MIND 24-7 fills the gap for those seeking help by being available right when they need it – 24 hours a day, 365 days a year. Using innovations in value-based care models to improve and expand access to care, MIND 24-7 not only enhances quality patient care, but reduces pressure on the system, reducing costly emergency room visits, in-patient treatment, and readmissions for crisis care.

Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel.

KP Consulting

KP Consulting Inc. is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Unilens Vision

Unilens Vision is a Seminole, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.